Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-07 6:52 pm Sale | 2025-04-03 | 13G | Aldeyra Therapeutics, Inc. ALDX | PERCEPTIVE ADVISORS LLC | 4,875,851 8.200% | -4,400,000 (-47.44%) | Filing History |
| 2025-04-03 4:18 pm Unchanged | 2025-03-31 | 13G | Ensysce Biosciences, Inc. ENSC | PERCEPTIVE ADVISORS LLC | 86,666 5.300% | 0 (Unchanged) | Filing History |
| 2025-03-31 4:10 pm Purchase | 2025-03-24 | 13G | Opus Genetics, Inc. IRD | PERCEPTIVE ADVISORS LLC | 4,510,501 9.990% | 4,510,501 (New Position) | Filing History |
| 2025-03-26 4:56 pm Purchase | 2024-12-13 | 13G | Inventiva S.A. IVA | PERCEPTIVE ADVISORS LLC | 5,555,555 5.800% | 5,555,555 (New Position) | Filing History |
| 2025-03-25 6:29 pm Unchanged | 2025-03-21 | 13D | Trinity Biotech plc TRIB | PERCEPTIVE ADVISORS LLC | 17,160,000 19.800% | 0 (Unchanged) | Filing History |
| 2025-02-28 9:15 pm Purchase | 2025-01-08 | 13G | Outset Medical, Inc. OM | PERCEPTIVE ADVISORS LLC | 375,000 9.500% | 250,774 (+201.87%) | Filing History |
| 2025-02-21 5:57 pm Purchase | 2025-02-13 | 13G | Edgewise Therapeutics, Inc. EWTX | PERCEPTIVE ADVISORS LLC | 5,164,487 5.500% | 5,164,487 (New Position) | Filing History |
| 2025-02-21 4:15 pm Purchase | 2025-02-19 | 13D | Solid Biosciences Inc. SLDB | PERCEPTIVE ADVISORS LLC | 11,934,679 15.600% | 5,000,001 (+72.10%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13D | Trinity Biotech plc TRIB | PERCEPTIVE ADVISORS LLC | 17,160,000 20.900% | 5,960,000 (+53.21%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Surrozen, Inc. SRZN | PERCEPTIVE ADVISORS LLC | 166,666 5.100% | 166,666 (New Position) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Ensysce Biosciences, Inc. ENSC | PERCEPTIVE ADVISORS LLC | 86,666 0.400% | 86,666 (New Position) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | RAPT Therapeutics, Inc. RAPT | PERCEPTIVE ADVISORS LLC | 735,000 4.500% | 467,506 (+174.77%) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Contineum Therapeutics, Inc. Class A Common Stock CTNM | PERCEPTIVE ADVISORS LLC | 1,441,249 5.600% | -125,420 (-8.01%) | Filing History |
| 2025-02-14 4:15 pm Unchanged | 2024-12-31 | 13G | Biodesix, Inc. BDSX | PERCEPTIVE ADVISORS LLC | 333,694 4.500% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Applied Therapeutics, Inc. APLT | PERCEPTIVE ADVISORS LLC | 2,860,000 2.400% | -7,145,000 (-71.41%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | PERCEPTIVE ADVISORS LLC | 163,935 2.500% | 12,502 (+8.26%) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,574,723 4.400% | -297,824 (-10.37%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Celcuity Inc. CELC | PERCEPTIVE ADVISORS LLC | 2,362,279 6.400% | 880,979 (+59.47%) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Amicus Therapeutics, Inc. FOLD | PERCEPTIVE ADVISORS LLC | 24,245,952 8.100% | -3,811,504 (-13.58%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | PERCEPTIVE ADVISORS LLC | 6,774,348 7.900% | 2,315,607 (+51.93%) | Filing History |